A Randomized, Comparative, Open Label Phase III Trial on Efficacy & Safety of Long-term Treatment With ICL670 Compared to Deferoxamine in Beta-thalassemia Patients With Transfusional Hemosiderosis
Latest Information Update: 27 Aug 2024
At a glance
- Drugs Deferasirox (Primary) ; Deferasirox
- Indications Haemosiderosis
- Focus Therapeutic Use
- Sponsors Novartis Pharmaceuticals Corporation
- 25 Jun 2017 Results (n=282) of retrospective analysis in subgroups of Italian patients assessing serum creatinine using patient data from the registration studies (studies 105, 106 and CICL670 0107, CICL670A0108, CICL670A0109), presented at the 22nd Congress of the European Haematology Association
- 08 Dec 2015 Results (n=219) assessing correlation of hepatocyte iron score and liver iron ratio with alanine aminotransferase from this and other trial (see profile 248870) presented at the 57th Annual Meeting and Exposition of the American Society of Hematology
- 05 Sep 2014 New trial record